ATE512660T1 - Zusammensetzungen mit peg-interferon-alpha- konjugaten und raffinose als kryoschutzmittel - Google Patents
Zusammensetzungen mit peg-interferon-alpha- konjugaten und raffinose als kryoschutzmittelInfo
- Publication number
- ATE512660T1 ATE512660T1 AT08720138T AT08720138T ATE512660T1 AT E512660 T1 ATE512660 T1 AT E512660T1 AT 08720138 T AT08720138 T AT 08720138T AT 08720138 T AT08720138 T AT 08720138T AT E512660 T1 ATE512660 T1 AT E512660T1
- Authority
- AT
- Austria
- Prior art keywords
- peg
- alpha conjugates
- interferon
- raffinose
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN412MU2007 | 2007-03-05 | ||
| PCT/IN2008/000114 WO2008107908A1 (en) | 2007-03-05 | 2008-02-29 | Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE512660T1 true ATE512660T1 (de) | 2011-07-15 |
Family
ID=39592752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08720138T ATE512660T1 (de) | 2007-03-05 | 2008-02-29 | Zusammensetzungen mit peg-interferon-alpha- konjugaten und raffinose als kryoschutzmittel |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2117514B1 (de) |
| JP (1) | JP5179521B2 (de) |
| AT (1) | ATE512660T1 (de) |
| BR (1) | BRPI0808259A2 (de) |
| EA (1) | EA019345B1 (de) |
| ES (1) | ES2365832T3 (de) |
| WO (1) | WO2008107908A1 (de) |
| ZA (1) | ZA200905690B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS20050177A (sr) | 2002-08-26 | 2007-06-04 | Pfizer Products Inc., | Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke |
| WO2010064258A2 (en) * | 2008-12-01 | 2010-06-10 | Intas Biopharmaceuticals Limited | Pharmaceutical formulations of interferon conjugates |
| US20100196272A1 (en) * | 2009-01-30 | 2010-08-05 | Neoprobe Corporation | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
| US20140017318A1 (en) * | 2012-07-10 | 2014-01-16 | Kevin O'Connell | Method to produce a medicinal product comprising a biologically active protein and the resulting product |
| MX2015005230A (es) * | 2012-10-26 | 2015-08-14 | Lupin Ltd | Composicion farmaceutica estable de peginterferon alfa-2b. |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
| TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
| MX9605717A (es) * | 1994-05-18 | 1998-05-31 | Inhale Therapeutic Syst | Metodos y composiciones para la formulacion de polvo seco de interferones. |
| CZ298429B6 (cs) * | 1997-04-28 | 2007-10-03 | Eli Lilly And Company | Stabilní lyofilizovaný prostredek |
| US6180096B1 (en) * | 1998-03-26 | 2001-01-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
| DK1820516T3 (da) * | 1999-02-22 | 2013-10-28 | Univ Connecticut | Nye albuminfrie faktor VIII-præparater |
| AU2001262939A1 (en) * | 2000-05-24 | 2001-12-03 | Eli Lilly And Company | Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
| EP1581260B1 (de) * | 2002-12-31 | 2014-09-17 | Nektar Therapeutics | Polymerreagentien mit einer keto- oder verwandten funktion |
| US20090214472A1 (en) * | 2004-03-01 | 2009-08-27 | Enzon Pharmaceuticals Inc. | Interferon-beta polymer conjugates |
| CA2576549C (en) | 2004-08-12 | 2011-01-18 | Schering Corporation | Stable pegylated interferon formulation |
-
2008
- 2008-02-29 BR BRPI0808259-6A patent/BRPI0808259A2/pt not_active IP Right Cessation
- 2008-02-29 ES ES08720138T patent/ES2365832T3/es active Active
- 2008-02-29 EA EA200970831A patent/EA019345B1/ru not_active IP Right Cessation
- 2008-02-29 WO PCT/IN2008/000114 patent/WO2008107908A1/en not_active Ceased
- 2008-02-29 JP JP2009552329A patent/JP5179521B2/ja not_active Expired - Fee Related
- 2008-02-29 EP EP08720138A patent/EP2117514B1/de active Active
- 2008-02-29 AT AT08720138T patent/ATE512660T1/de not_active IP Right Cessation
-
2009
- 2009-08-17 ZA ZA200905690A patent/ZA200905690B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200970831A1 (ru) | 2010-02-26 |
| EP2117514A1 (de) | 2009-11-18 |
| JP5179521B2 (ja) | 2013-04-10 |
| WO2008107908A1 (en) | 2008-09-12 |
| ES2365832T3 (es) | 2011-10-11 |
| JP2010520270A (ja) | 2010-06-10 |
| EP2117514B1 (de) | 2011-06-15 |
| ZA200905690B (en) | 2010-05-26 |
| BRPI0808259A2 (pt) | 2014-07-08 |
| EA019345B1 (ru) | 2014-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE512660T1 (de) | Zusammensetzungen mit peg-interferon-alpha- konjugaten und raffinose als kryoschutzmittel | |
| MX2010010508A (es) | Composiciones de absorcion de sebo. | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| MX390779B (es) | Composición farmacéutica. | |
| BR122013025375B8 (pt) | compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
| BRPI0815395A2 (pt) | Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição. | |
| MA32369B1 (fr) | Composes de benzene sulfonamide thiazole et oxazole | |
| TN2009000398A1 (en) | 5,6-dihydro-1h-pyridin-2-one compounds | |
| CO6190510A2 (es) | Inhibidores del virus de la hepatitis c | |
| CO6741214A2 (es) | Composiciones pesticidas y procesos relacionados | |
| BR112012012460A8 (pt) | método de liofilização, composições e kits | |
| EA201170703A1 (ru) | Производные адамантилбензамида | |
| TR201900207T4 (tr) | Faktör VIII Formülasyonları | |
| EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| EA200970509A1 (ru) | Композиции конъюгатов пэг-интерферон альфа | |
| CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
| TN2010000074A1 (en) | Cyclic depsipeptides | |
| EA201201406A1 (ru) | Фунгицидные смеси ii, содержащие хиназолины | |
| PA8781701A1 (es) | Derivados de 7-alquinil-1,8- naftiridonas, su preparaciones y su aplicacion en terapeutica | |
| EA201201623A1 (ru) | Лечение диабета 2 типа | |
| ECSP109961A (es) | Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica | |
| GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| EA200701306A1 (ru) | Лиофилизация виросом | |
| BR112012013199A2 (pt) | composto, composição farmacêutica, e , uso de um composto | |
| CR11335A (es) | Nuevas composiciones a base de taxoides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |